{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:01:17Z","timestamp":1784959277849,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 vaccines have significantly reduced mortality and are safe for healthy children; however, research in pediatric populations with juvenile immune-mediated inflammatory diseases (IMIDs) is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Brazilian multicenter longitudinal SAFER-Study evaluates immunogenicity and safety of the BNT162b2\/Pfizer vaccine in IMID patients. The juvenile cohort enrolled patients aged 12\u201317 years between August and December 2021 and compared them with adults under 40 years from the adult cohort. Safety was assessed by monitoring post-vaccination adverse events (AEs), immunogenicity was measured by IgG antibodies against the SARS-CoV-2 spike receptor-binding domain and seroconversion rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 123 participants were included: 86 adolescents and 37 adult controls. In adolescents, local AEs were most frequent; no serious or life-threatening AEs occurred. Significant increases in IgG-S levels were observed after the two doses in both cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Seroconversion after the second dose reached 97% overall and 100% after the third dose. In juvenile SLE and JIA patients, vaccination did not significantly affect disease activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The BNT162b2 vaccine was safe and immunogenic in adolescents with IMIDs, including those with high immunosuppression and comorbidities, showing similar responses to adults. These findings support vaccination in this vulnerable population and contribute to evidence-based recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>BNT162b2 COVID-19 vaccine demonstrated a favorable safety profile and immunogenicity in adolescents with juvenile immune-mediated inflammatory diseases (IMID), with responses comparable to those observed in adults.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Real life data on this population remain limited, and further evidence regarding vaccine safety and immunogenicity is needed. This study represents the first multicenter, longitudinal registry of Brazilian adolescents with IMID receiving BNT162b2.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Comprehensive data on the safety and immunogenicity of BNT162b2 in highly immunosuppressed adolescents with IMID and comorbidities are crucial to guide clinical decision-making, mitigate vaccine hesitancy, and enhance vaccination coverage within this vulnerable population.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-04836-5","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:04:03Z","timestamp":1784916243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease"],"prefix":"10.1038","author":[{"given":"Carolina S. E.","family":"Gadelha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Terreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"N Burian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline C. M.","family":"da Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty L. L. L.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Elizabeth","family":"Checon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yhasmin O. G.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L\u00facia E.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Maria P. F.","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo P. V.","family":"de Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00e9lia P. C.","family":"Schimidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo M.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odirlei Andr\u00e9","family":"Monticielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgard T.","family":"dos Reis-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em\u00edlia I.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane A.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gecilmara S.","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleice","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SAFER STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Principal Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty Lysie Libardi Lira","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L\u00facia Euz\u00e9bio","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Poubel Vieira","family":"de Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Karla Guedes","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejane Maria Rodrigues","family":"de Abreu Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Alves","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia Inoue","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane Angelina","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda Aparecida","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgard Torres dos Reis","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odirlei Andr\u00e9","family":"Monticielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"de Medeiros Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gecilmara Salviato","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Valim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria","family":"Valim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"4836_CR1","unstructured":"World Health Organization data.who.int, WHO Coronavirus (COVID-19) dashboard > Deaths. Available at: https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=o Accessed on: feb 15, 2025."},{"key":"4836_CR2","unstructured":"World Health Organization data.who.int, WHO Coronavirus (COVID-19) dashboard > cases. Available at: https:\/\/data.who.int\/dashboards\/covid19\/cases. Accessed on: feb 15, 2025."},{"key":"4836_CR3","doi-asserted-by":"crossref","unstructured":"Mehraeen, E. et al. COVID-19 in pediatrics: A systematic review of current knowledge and practice. Infect. Disord. Drug Targets. 22, e290921196908 (2022).","DOI":"10.2174\/1871526521666210929121705"},{"key":"4836_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ppul.25344","volume":"56","author":"MK Siebach","year":"2021","unstructured":"Siebach, M. K., Piedimonte, G. & Ley, S. H. COVID-19 in childhood: Transmission, clinical presentation, complications and risk factors. Pediatr. Pulmonol. 56, 1342\u20131356 (2021).","journal-title":"Pediatr. Pulmonol."},{"key":"4836_CR5","unstructured":"United Nations Children\u2019s Fund (UNICEF). Child mortality and COVID-19. Available at: https:\/\/data.unicef.org\/topic\/child-survival\/covid-19\/. Accessed on: feb 15, 2025."},{"key":"4836_CR6","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00431-023-04958-6","volume":"182","author":"P Sadeghi","year":"2023","unstructured":"Sadeghi, P., Pezeshki, P. S. & Rezaei, N. Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders. Eur. J. Pediatr. 182, 2967\u20132988 (2023).","journal-title":"Eur. J. Pediatr."},{"key":"4836_CR7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/art.42030","volume":"74","author":"R Conway","year":"2022","unstructured":"Conway, R. et al. COVID-19 Global Rheumatology Alliance. SARS-CoV-2 Infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 74, 766\u2013775 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"4836_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2022-222241","volume":"81","author":"L Kearsley-Fleet","year":"2022","unstructured":"Kearsley-Fleet, L. et al. CARRA Registry Investigators; COVID-19 Global Pediatric Rheumatology Database Investigators; Natter M, Hyrich KL. Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 81, 998\u20131005 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"4836_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446\u2013455 (2018).","journal-title":"Mol. Ther."},{"key":"4836_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"4836_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12969-023-00848-1","volume":"21","author":"M Hamad Saied","year":"2023","unstructured":"Hamad Saied, M. et al. The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. Pediatr. Rheumatol. Online J. 21, 80 (2023).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"4836_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4836_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. COVE study group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4836_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/vaccines9101102","volume":"9","author":"M Lv","year":"2021","unstructured":"Lv, M. et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review. Vaccines (Basel) 9, 1102, https:\/\/doi.org\/10.3390\/vaccines9101102 (2021).","journal-title":"Vaccines (Basel)"},{"key":"4836_CR15","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/rheumatology\/keac103","volume":"61","author":"M Heshin-Bekenstein","year":"2022","unstructured":"Heshin-Bekenstein, M. et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatol. (Oxf.) 61, 4263\u20134272 (2022).","journal-title":"Rheumatol. (Oxf.)"},{"key":"4836_CR16","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1093\/rheumatology\/keac105","volume":"61","author":"JG Yeo","year":"2022","unstructured":"Yeo, J. G. et al. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases. Rheumatol. (Oxf.) 61, 4472\u20134481 (2022).","journal-title":"Rheumatol. (Oxf.)"},{"key":"4836_CR17","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1093\/rheumatology\/keac140","volume":"61","author":"\u00d6 Akg\u00fcn","year":"2022","unstructured":"Akg\u00fcn, \u00d6. et al. Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatol. (Oxf.) 61, 4482\u20134490 (2022).","journal-title":"Rheumatol. (Oxf.)"},{"key":"4836_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/vaccines11040819","volume":"11","author":"M Heshin-Bekenstein","year":"2023","unstructured":"Heshin-Bekenstein, M. et al. Safety and immunogenicity following the second and third doses of the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicentre study. Vaccines (Basel) 11, 819 (2023).","journal-title":"Vaccines (Basel)"},{"key":"4836_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12969-024-01003-0","volume":"22","author":"T \u0160inkovec Sav\u0161ek","year":"2024","unstructured":"\u0160inkovec Sav\u0161ek, T. et al. Serological response after COVID-19 infection compared to vaccination against COVID-19 in children with autoimmune rheumatic diseases. Pediatr. Rheumatol. Online J. 22, 68 (2024).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"4836_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/vaccines12121367","volume":"12","author":"KLLL Machado","year":"2024","unstructured":"Machado, K. L. L. L. et al. Immunogenicity and safety according to immunosuppressive drugs and different COVID-19 vaccine platforms in immune-mediated disease: data from SAFER cohort. Vaccines (Basel) 12, 1367 (2024).","journal-title":"Vaccines (Basel)"},{"key":"4836_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42358-019-0056-x","volume":"59","author":"GS Pileggi","year":"2019","unstructured":"Pileggi, G. S. et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Adv. Rheumatol. 59, 17 (2019).","journal-title":"Adv. Rheumatol."},{"key":"4836_CR22","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u201391 (2002).","journal-title":"J. Rheumatol."},{"key":"4836_CR23","doi-asserted-by":"crossref","unstructured":"Lawson-Tovey, S. et al. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. RMD Open. 8, e002322 (2022).","DOI":"10.1136\/rmdopen-2022-002322"},{"key":"4836_CR24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/apa.16652","volume":"112","author":"B Sahn","year":"2023","unstructured":"Sahn, B. et al. The safety of COVID-19 vaccination in immunocompromised children and young adults with immune-mediated inflammatory disease. Acta Paediatr. 112, 794\u2013801 (2023).","journal-title":"Acta Paediatr."},{"key":"4836_CR25","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1093\/rheumatology\/kead047","volume":"62","author":"CB Chighizola","year":"2023","unstructured":"Chighizola, C. B. et al. Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: Tolerability and impact on disease activity. Rheumatol. (Oxf.) 62, 3146\u20133150 (2023).","journal-title":"Rheumatol. (Oxf.)"},{"key":"4836_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck Jr","year":"2021","unstructured":"Frenck, R. W. Jr et al. C4591001 clinical trial group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 385, 239\u2013250 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4836_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"4836_CR28","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"4836_CR29","first-page":"100149","volume":"5","author":"LG Barberia","year":"2022","unstructured":"Barberia, L. G., Bastos, L. S. & de Sousa, T. C. M. School reopening and COVID-19 in Brazil. Lancet Reg. Health Am. 5, 100149 (2022).","journal-title":"Lancet Reg. Health Am."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04836-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:31:40Z","timestamp":1784957500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":29,"alternative-id":["4836"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-04836-5","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the National Research Ethics Committee (CONEP) with study protocol number (CAAE) 43479221.0.1001.5505 and by each regional Ethics Committee. Informed consent was obtained from each participant and their parents.","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}